Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith

A technology of hematopoietic stem cells and stem cells, which is applied in the treatment of ocular vascular diseases and the field of hematopoietic stem cell groups, can solve the problems of uncertain cell number and unclear mechanism, and achieve the effect of protecting retinal neurons and photoreceptors

Inactive Publication Date: 2006-09-13
THE SCRIPPS RES INST
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although these cells have been used in several experimental models of angiogenesis, the mechanism by which EPCs act on neovascularization remains unclear, and strategies to effectively increase the number of cells targeting specific vessels have not been identified

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
  • Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
  • Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0066] Example 1. Cell Separation and Enrichment: Mouse Lin - Preparation of HSC populations A and B

[0067] General Procedures. All in vivo evaluations were performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals, and all evaluation procedures were approved by the Animal Care and Use Committee of the Scripps Research Institute (TSRI, La Jolla, CA). Bone marrow cells were extracted from B6.129S7-Gtrosa26, Tie-2GFP, ACTbEGFP, FVB / NJ (rd / rd mice) or Balb / cBYJ adult mice (The Jackson Laboratory, ME).

[0068] By using HISTOPAQUE  Density gradient centrifugation of sucrose gradients (Sigma, St.Louis, MO) to isolate mononuclear cells was used in mice for Lin - Selected biotin-conjugated lineage population antibodies (CD45, CD3, Ly-6G, CD 11, TER-119, Pharmingen, San Diego, CA) were used to label these monocytes. Using magnetic separation equipment (AUTOMACS TM sorter, Miltenyi Biotech, Auburn, CA) from Lin - Positive lineage segregation in HSC ...

Embodiment 2

[0073] Example 2. Intravitreal Administration of Cells in a Murine Model

[0074] A portion of eyelid tissue was cut in the eyelid of the mouse using a sharp blade to expose the eyeball from P2 to P6. The lineage-negative HSC population A of the present invention was then injected intravitreally using a 33-gauge (Hamilton, Reno, NV) needle syringe (about 10 in about 0.5 μl to about 1 μl of cell culture medium). 5 cells).

Embodiment 3

[0075] Example 3. EPC transfection

[0076] According to the manufacturer's manual, using FuGENE TM 6 Transfection reagent (Roche, Indianapolis, IN), using the T2 fragment encoding TrpRS and containing His 6 Tag (SEQ ID NO: 1, Fig. 7) DNA transfection mouse Lin - HSC (group A). Lin - HSC cells (approximately 10 per ml 6 cells) were suspended in opti-MEM medium (Invitrogen, Carlsbad, CA) containing stem cell factor (PeproTech, Rocky Hill, NJ). Then DNA (about 1 μg) and FuGENE reagent (about 3 μl) were added, and the mixture was incubated at about 37° C. for about 18 hours. After incubation, cells are washed and harvested. The transfection efficiency of this system was confirmed to be about 17% by FACS analysis. T2 products were confirmed by Western blot. with His 6 The amino acid sequence of the tagged T2-TrpRS is shown in SEQ ID NO: 2 in FIG. 8 .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Isolated, mammalian, adult bone marrow-derived, lineage negative hematopoietic stem cell populations (Lin - HSCs) containing endothelial progenitor cells (EPCs) have been transfected with therapeutically useful genes. The transfected isolated stem cell populations of the invention are useful for delivering genes to the eye for cell-based gene therapy. Methods of preparing transfected isolated stem cell populations of the invention, and methods of treating ocular diseases and injury are also described.

Description

[0001] This application is a divisional application of an invention patent application whose application date is April 28, 2004, and whose application number is 200480018990.6, and whose invention name is the same as that of the present invention. [0002] Cross References to Related Applications [0003] This application is a continuation-in-part of U.S. Patent Application 10 / 628,783, filed July 25, 2003, a provisional application claiming 60 / 398,522, filed July 25, 2002, and 60 / 467,051, filed May 2, 2003 The entire disclosure content of the above-mentioned application is incorporated into this application by reference. [0004] Statement of Government Interest [0005] Part of the work described herein was supported by National Cancer Institute grant CA92577 and National Institutes of Health grants EY11254, EY12598, and EY125998. The US Government has certain rights in this invention. technical field [0006] The present invention relates to isolated, mammalian, lineage-n...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/08C12N15/52C12N15/85A61K35/12A61P27/02C12N5/078A61K35/28A61K48/00A61P9/10A61P27/12C12N5/071C12N5/074C12N5/0789C12N5/10C12N15/09G01N33/48G01N33/53
CPCC12N5/0647A61K2035/124C12N5/0692A61K35/12A61K48/00A61P7/02A61P7/06A61P9/10A61P9/14A61P25/00A61P27/02A61P27/12A61P41/00A61P43/00C12N5/10
Inventor M·弗里德兰德A·奥塔尼K·达西尔瓦哈内坎普
Owner THE SCRIPPS RES INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap